Mast cell activation syndromes in clinical practice: diagnostic challenges, phenotypes, and real-life management
Department of Allergy and Immunology, University of Health Sciences, Süreyyapaşa Training and Research Hospital, Istanbul, Türkiye
Department of Internal Medicine, Division of Haematology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Türkiye
Adv
Dermatol Allergol
-
Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol 2010; 126: 1099-104.e4.
Valent P. Mast cell activation syndromes: definition and classification. Allergy 2013; 68: 417-24.
Afrin LB, Ackerley MB, Bluestein LS, et al. Diagnosis of mast cell activation syndrome: a global ”consensus-2”. Diagnosis 2020; 8: 137-52.
Özdemir Ö, Kasımoğlu G, Bak A, et al. Mast cell activation syndrome: an up-to-date review of literature. World J Clin Pediatr 2024; 13: 92813.
Valent P, Hartmann K, Bonadonna P, et al. Mast cell activation syndromes: Collegium Internationale Allergologicum update 2022. Int Arch Allergy Immunol 2022; 183: 693-705.
Afrin LB, Self S, Menk J, et al. Characterization of mast cell activation syndrome. Am J Med Sci 2017; 353: 207-15.
Gülen
T, Hägglund H, Dahlén B, et al. High prevalence of anaphylaxis in
patients with systemic mastocytosis –
a single-centre
experience. Clin Exp Allergy 2014; 44: 121-9.
Brockow K, Jofer C, Behrendt H, et al. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63: 226-32.
González de Olano D, de la Hoz Caballer B, Núñez López R, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 2007; 37: 1547-55.
Gulen T. Using the right criteria for MCAS. Curr Allergy Asthma Rep 2024; 24: 39-51.
Valent P, Akin C, Bonadonna P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract 2019; 7: 1125-33.e1.
Gülen T, Akin C, Bonadonna P, et al. Selecting the right criteria and proper classification to diagnose mast cell activation syndromes: a critical review. J Allergy Clin Immunol Pract 2021; 9: 3918-28.
Schwartz LB, Metcalfe DD, Miller JS, et al. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987; 316: 1622-6.
Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006; 26: 451-63.
Mateja A, Wang Q, Chovanec J, et al. Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis. J Allergy Clin Immunol 2022; 149: 1010-17.e10.
Gülen T, Akin C. Pharmacotherapy of mast cell disorders. Curr Opin Allergy Clin Immunol 2017; 17: 295-303.
Lemal R, Fouquet G, Terriou L, et al. Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS. J Allergy Clin Immunol Pract 2019; 7: 2387-95.e3.
Matheny MV, Craig T, Al-Shaikhly T. Systematic review of omalizumab for refractory clonal and non-clonal mast cell activation syndrome. Allergy Asthma Proc 2025; 46: 11-8.
Golden DBK, Wang J, Waserman S, et al. Anaphylaxis: a 2023 practice parameter update. Ann Allergy Asthma Immunol 2024; 132: 124-76.
Gülen T. A puzzling mast cell trilogy: anaphylaxis, MCAS, and mastocytosis. Diagnostics 2023; 13: 3307.
